Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia
暂无分享,去创建一个
[1] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[2] M. Minden,et al. Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy , 2010, Clinical Cancer Research.
[3] S. Grant,et al. Exploiting cellular pathways to develop new treatment strategies for AML. , 2010, Cancer treatment reviews.
[4] M. Caligiuri,et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[6] Yun Dai,et al. New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.
[7] Kristina Masson,et al. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. , 2009, Cellular signalling.
[8] H. Yoshida,et al. Interleukin 27: a double‐edged sword for offense and defense , 2009, Journal of leukocyte biology.
[9] E. Vellenga,et al. Single-Cell STAT5 Signal Transduction Profiling in Normal and Leukemic Stem and Progenitor Cell Populations Reveals Highly Distinct Cytokine Responses , 2009, PloS one.
[10] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[11] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[12] J. McCubrey,et al. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia , 2009, Expert opinion on investigational drugs.
[13] V. P. Savitski,et al. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells , 2009, Hematology.
[14] G. Marcucci. Molecular markers in acute myeloid leukemia. , 2009, Clinical advances in hematology & oncology : H&O.
[15] S. Meshinchi,et al. Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia , 2009, Clinical Cancer Research.
[16] O. Hammarsten,et al. Numerical Analysis of Etoposide Induced DNA Breaks , 2009, PloS one.
[17] D. Hommes,et al. Regulation of p110δ PI 3-Kinase Gene Expression , 2009, PloS one.
[18] R. Germain,et al. Navigating the network: signaling cross-talk in hematopoietic cells , 2009, Nature Immunology.
[19] C. Bloomfield,et al. Molecular signatures in acute myeloid leukemia , 2009, Current opinion in hematology.
[20] K. Döhner,et al. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia , 2009, Current opinion in hematology.
[21] B. Vanhaesebroeck,et al. Regulation of phosphoinositide 3-kinase expression in health and disease. , 2009, Trends in biochemical sciences.
[22] P. Vogt,et al. PI 3-kinase and cancer: changing accents. , 2009, Current opinion in genetics & development.
[23] Jonathan M Irish,et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. , 2008, Cancer cell.
[24] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[25] E. Vellenga,et al. Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity Levels , 2008, Molecular and Cellular Biology.
[26] Anne Rascle,et al. In vivo identification of novel STAT5 target genes , 2008, Nucleic acids research.
[27] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[28] V. Ling,et al. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. , 2008, Experimental hematology.
[29] H. Nakauchi,et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. , 2008, Blood.
[30] J Wade Harper,et al. The DNA damage response: ten years after. , 2007, Molecular cell.
[31] M. Garrett,et al. CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin? , 2007, Nature Reviews Cancer.
[32] H. Kantarjian,et al. Progress in the treatment of acute myeloid leukemia , 2007, Cancer.
[33] S. Rane,et al. Hematopoietic cytokine receptor signaling , 2007, Oncogene.
[34] Danielle Boller,et al. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. , 2007, Critical reviews in oncology/hematology.
[35] M. Mann,et al. Is Proteomics the New Genomics? , 2007, Cell.
[36] E. D. de Vries,et al. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. , 2007, Critical reviews in oncology/hematology.
[37] C. Bloomfield,et al. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review , 2007, British journal of haematology.
[38] J. Blenis,et al. RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation* , 2007, Journal of Biological Chemistry.
[39] K. D. Bunting,et al. STAT5 signaling in normal and pathologic hematopoiesis. , 2007, Frontiers in bioscience : a journal and virtual library.
[40] Myung-Shik Lee,et al. STAT1 as a key modulator of cell death. , 2007, Cellular signalling.
[41] Jonathan M Irish,et al. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. , 2006, Blood.
[42] G. Nolan,et al. Kinetics of B Cell Receptor Signaling in Human B Cell Subsets Mapped by Phosphospecific Flow Cytometry1 , 2006, The Journal of Immunology.
[43] T. Kishimoto. Interleukin-6: discovery of a pleiotropic cytokine , 2006, Arthritis research & therapy.
[44] S. Morrison,et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.
[45] J. Pierre,et al. JAK/STAT signal transduction: regulators and implication in hematological malignancies. , 2006, Biochemical pharmacology.
[46] Garry P Nolan,et al. Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level. , 2006, Current opinion in chemical biology.
[47] G. Nolan,et al. Mapping normal and cancer cell signalling networks: towards single-cell proteomics , 2006, Nature Reviews Cancer.
[48] E. Fish,et al. Stats: multifaceted regulators of transcription. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[49] D. Gilliland,et al. Drug therapy for acute myeloid leukemia. , 2005, Blood.
[50] Chunaram Choudhary,et al. Signal Transduction of Oncogenic Flt3 , 2005, International journal of hematology.
[51] E. Solary,et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .
[52] E. Estey,et al. Acute Myelogenous Leukemia , 2005 .
[53] Jonathan M Irish,et al. Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.
[54] Peter O. Krutzik,et al. Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[55] Yoo Hong Min,et al. Phosphatase and tensin homologue phosphorylation in the C‐terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome , 2003, British journal of haematology.
[56] Heinz Baumann,et al. Signal transducer and activator of transcription proteins in leukemias. , 2003, Blood.
[57] I. Jolliffe. Principal Component Analysis , 2002, International Encyclopedia of Statistical Science.
[58] J. Bromberg. Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.
[59] J. Darnell,et al. The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.
[60] P. Coffer,et al. The role of STATs in myeloid differentiation and leukemia , 2000, Oncogene.
[61] Thomas C. Chen,et al. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines , 1994, FEBS letters.
[62] M. Loken,et al. CD45 Gating for Routine Flow Cytometric Analysis of Human Bone Marrow Specimens , 1993, Annals of the New York Academy of Sciences.
[63] M. Minden,et al. Dynamic single cell network profiles in AML are associated with patient response to standard induction therapy Running Title: SCNP in AML Induction Therapy Response , 2010 .
[64] O. Meyuhas. Physiological roles of ribosomal protein S6: one of its kind. , 2008, International review of cell and molecular biology.
[65] T. Pawson,et al. Network medicine , 2008, FEBS letters.
[66] B. Löwenberg. Acute myeloid leukemia: the challenge of capturing disease variety. , 2008, Hematology. American Society of Hematology. Education Program.
[67] E. Solary,et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.
[68] 정준원,et al. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome , 2003 .
[69] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[70] Z. Xia,et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. , 2002, Blood.